Efficacy and Safety of Oral Gene III ® L-Ergothioneine Capsules in Primary Dysmenorrhea: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Read full text Summarise with VIRAT
Authors: Cong Guo, Wei Liu, Wei Ding, Juan Cao, Tong Tong, Fengjuan Liu, Guohua Xiao
Cited by: 0
References: 15

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Abstract Purpose To evaluate the efficacy and safety of oral L-ergothioneine (EGT) in alleviating pain and associated symptoms in women with primary dysmenorrhea (PD). Methods In this randomized, double-blind, placebo-controlled trial, 40 women with PD (aged 18–30 years) were randomized (1:1) to receive EGT capsules (120 mg/day) or a matching placebo for 3 consecutive menstrual cycles. Outcomes evaluated at baseline and post-cycle included peak pain (Visual Analog Scale, VAS), Dysmenorrhea Symptom Score, and the COX Menstrual Symptom Scale (CMSS). Results EGT significantly improved PD symptoms over 3 cycles. Mean VAS for peak pain decreased from 4.80 ± 1.12 to 2.32 ± 1.59 in the EGT group (p < 0.001), compared to a non-significant reduction (4.10 ± 1.30 to 3.45 ± 1.69) in the placebo group. The between-group difference at cycle 3 was significant (p < 0.01). A linear mixed-model confirmed a significant Time × Group interaction (p < 0.001), showing an accelerated decline in symptom severity for EGT. Furthermore, 84% of EGT-treated patients achieved ≥50% VAS reduction versus 35% in the placebo group (p = 0.003). Serum inflammatory biomarkers showed no significant between-group differences or correlation with VAS improvements, suggesting EGT’s analgesic effects likely operate via cytoprotective pathways independent of classical inflammatory cascades. No adverse events were reported. Conclusion Oral EGT supplementation (120 mg/day) effectively and progressively mitigates menstrual pain and systemic symptoms in PD, offering a well-tolerated, non-pharmacological nutritional intervention. Trial Registration ChiCTR2500112557; Retrospectively registered on 2025-11-17.

Fields of Study & Subjects

Menstrual Health and Disorders Endometriosis Research and Treatment Inflammatory mediators and NSAID effects

Publication details

Journal / source
medRxiv
Publication date
27 March 2026
Language
EN
Document type
Preprint